Acute pulmonary embolism (PE) is a significant cause of mortality and morbidity across the globe. Over the last few decades, there have been major therapeutic advances in acute PE management, including catheter-based therapy. However, the effectiveness of catheter-based therapy in acute PE is not supported by Level I evidence, making the use of this promising treatment rather controversial and ambiguous. In this paper, we discuss the risk stratification of acute PE and review the medical and endovascular treatment options. We also summarize and review the data supporting the use of endovascular treatment options in acute PE and describe the potential role of the PE response team.
Keywords: Chronic thromboembolic pulmonary hypertension; FlowTriever; Massive pulmonary embolism; Pulmonary embolism response team; Thrombectomy.
© 2020 Published by Scientific Scholar on behalf of Journal of Clinical Imaging Science.